- Global Pharma News & Resources

Johnson Matthey to manufacture regulatory starting materials for Sarepta Therapeutics’ RNA technology-based clinical and commercial programmes

Johnson Matthey (JM), a global leader in science that enables a cleaner and healthier world, has entered into a five-year supply agreement with Sarepta Therapeutics, Inc. to continue supplying regulatory starting materials to support Sarepta’s phosphorodiamidate morpholino oligomer (PMO) and peptide phosphorodiamidate morpholino oligomer (PPMO) programmes used for the treatment of Duchenne Muscular Dystrophy.

Sarepta is the leader in precision genetic medicine for rare diseases and working to change the lives of people living with rare diseases. Johnson Matthey’s Innovator Products & Solutions business that provides Custom Development and Manufacturing Services (CDMO) will produce these synthetic regulatory starting materials at their facilities in West Deptford, NJ and Devens, MA using their commercial-scale production trains.

“JM is delighted to further strengthen our relationship with Sarepta through this manufacturing agreement,” said Alex Zahiri, Vice President, Innovator Products & Solutions (CDMO) business, Johnson Matthey. “Our collaboration with Sarepta signifies our continued commitment to existing and future PPMO and PMO programs, and Sarepta’s mission of engineering precision medicine for rare, devastating diseases.”

“Sarepta’s growing pipeline requires best in class manufacturing expertise in order to deliver on our commitment to patients. We are excited to expand and extend our agreement with Johnson Matthey as a manufacturing partner for our PMO and PPMO platforms,” said Bill Ciambrone, Executive Vice President, Technical Operations, Sarepta.

As leaders in the complex technologies behind a wide variety of healthcare products and services, Johnson Matthey provides its global customers with expertise in complex active pharmaceutical ingredient development and manufacture, solid form sciences, particle engineering, and catalysts. JM uses its cutting-edge science to create solutions that improve healthcare and make a real difference to the world around us.

About Johnson Matthey

Johnson Matthey is a global leader in science that enables a cleaner and healthier world. With over 200 years of sustained commitment to innovation and technological breakthroughs, we improve the performance, function and safety of our customers’ products and in 2020 we received the London Stock Exchange’s Green Economy Mark, given to companies that derive more than 50% of revenues from environmental solutions. Our science has a global impact in areas such as low emission transport, pharmaceuticals, chemical processing and making the most efficient use of the planet’s natural resources. Today more than 14,000 Johnson Matthey professionals collaborate with our network of customers and partners to make a real difference to the world around us. For more information, visit

Editor Details

  • Company:
    • Sarepta Therapeutics
  • Name:
    • Sarepta Therapeutics
Last Updated: 07-Sep-2020